(Press-News.org) OKLAHOMA CITY – A newly approved National Cancer Institute-funded clinical trial aims to improve survival for head and neck cancer patients whose disease returns after radiation therapy – a setback that affects up to 40% of patients and is often associated with poor outcomes.
For these patients, surgery is currently the standard treatment, typically targeting tumors in the mouth, throat or lymph nodes of the neck. This Phase II trial will examine whether giving chemotherapy, or chemotherapy combined with immunotherapy, before surgery can improve survival compared with surgery alone.
“Even when a patient is a good surgical candidate, the operation is often aggressive and life-altering. It can mean losing the voice box, removing much of the tongue, or risking serious complications in the neck, and despite all that, outcomes are still not where we want them to be. We hope this trial identifies a treatment that will help patients live longer without the cancer returning,” said Christina Henson, M.D., associate professor at the University of Oklahoma College of Medicine and radiation oncologist at the OU Health Stephenson Cancer Center. Henson is the radiation oncology chair for the trial, which will enroll patients in Oklahoma and across the United States.
Patients deemed surgical candidates will be randomly assigned to receive chemotherapy (carboplatin and paclitaxel) before surgery; the same chemotherapies plus the immunotherapy drug cemiplimab before surgery; or surgery alone. Cemiplimab, which harnesses the body’s own immune system to fight the cancer, is a PDL1 inhibitor. The drug targets cancers that are positive for PDL1, a protein marker indicating the tumor may be vulnerable to immunotherapy. Most head and neck cancers are PDL1-positive, Henson said.
Henson’s colleague Mark Newpower, Ph.D., an assistant professor in the OU College of Medicine, is the medical physics chair for the trial. Patients with especially high-risk cancer may receive radiation therapy following surgery.
“We have worked to standardize the technical details of this trial. It has been gratifying to contribute the institutional knowledge of our radiation oncology department,” said Newpower, who is the lead proton physicist for OU Health Stephenson Cancer Center.
For more information about the trial, visit https://clinicaltrials.gov/study/NCT07195734.
###
About the University of Oklahoma
Founded in 1890, the University of Oklahoma is a public research university with campuses in Norman, Oklahoma City and Tulsa. As the state’s flagship university, OU serves the educational, cultural, economic and health care needs of the state, region and nation. In Oklahoma City, the OU Health Campus is one of the nation’s few academic health centers with seven health profession colleges located on the same campus. The OU Health Campus serves approximately 4,000 students in more than 70 undergraduate and graduate degree programs spanning Oklahoma City and Tulsa and is the leading research institution in Oklahoma. For more information about the OU Health Campus, visit www.ouhsc.edu.
END
New research shows that after the body’s defenses kill the virus behind COVID-19, leftover digested chunks of SARS-CoV-2 spike protein can target specific immune cells based on their shape. The revelations could explain why certain populations of cells that detect and fight infection are depleted in patients with severe COVID-19, and shed light on the omicron variant’s milder symptoms.
The study, published in the Proceedings of the National Academy of Sciences, may launch a line of inquiry that informs new strategies for quelling the most serious symptoms of COVID-19. Led by a UCLA team, the scientific collaboration ...
Virginia Tech researchers discovered an indication hidden in the brain that may help doctors identify children suffering from a rare genetic disease earlier. Their findings were published recently in EMBO Molecular Medicine.
Leigh syndrome is a severe neurological disorder that affects the mitochondria, which are energy factories found in almost all the cells of the body. This disease typically appears in infancy and can progress rapidly, leading to limited treatment options and poor survival rates.
Prenatal tests for mitochondrial disorders like Leigh syndrome ...
Microbes across Earth’s coldest regions are becoming more active as glaciers, permafrost and sea ice thaw, accelerating carbon release and potentially amplifying climate change, according to a new international review from McGill University.
Drawing on data from polar and alpine environments worldwide, the researchers found that warming is driving faster microbial metabolism, increasing the breakdown of organic matter and the release of greenhouse gases such as carbon dioxide and methane into the ...
NEW YORK, NY– Today, the Vertebrate Genome Laboratory, led by Erich Jarvis and Co-Directors Giulio Formenti and Jennifer Balacco, at The Rockefeller University, has received funding as part of Google.org's $20 million AI for Science Fund to support organizations focused on cutting-edge AI for science research. The funding has been awarded to twelve academic and nonprofit organizations around the world that are using AI to address increasingly complex problems at the intersections of various disciplines of science. The proportion ...
Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the University of British Columbia are extending those possibilities to the skin for the first time.
The UBC team, together with researchers from the Berlin Institute of Health at Charité in Germany, has developed the first gene therapy capable of correcting faulty genes when applied directly to human skin. Outlined today in a paper published in Cell Stem Cell, the breakthrough could lead ...
PORTLAND, Ore. – Scientists at Oregon State University have developed a new nanomaterial that triggers a pair of chemical reactions inside cancer cells, killing the cells via oxidative stress while leaving healthy tissues alone.
The study led by Oleh and Olena Taratula and Chao Wang of the OSU College of Pharmacy was published this week in Advanced Functional Materials.
The findings advance the field of chemodynamic therapy or CDT, an emerging treatment approach based on the distinctive biochemical environment found in ...
A solar energy generation technology once considered limited in its potential is poised for significant growth in the United States.
That’s the conclusion of a team of scientists who analyzed the outlook for cadmium telluride photovoltaics in research published in the peer-reviewed journal Joule.
University of Toledo physicists including Dr. Michael Heben, a Distinguished University Professor and McMaster Chair and Director of the Wright Center for Photovoltaics Innovation and Commercialization, collaborated with partners at the U.S. Department of Energy’s National Laboratory ...
WEST LAFAYETTE, Ind. — A Purdue University team led by Kyle Cottrell has discovered a new therapeutic target for triple-negative breast cancer.
“Triple-negative breast cancer is a particularly deadly form of breast cancer that currently lacks targeted therapies,” said Cottrell, an assistant professor of biochemistry. Cottrell, biochemistry graduate student Addison Young and their co-authors describe the discovery in the journal RNA.
The laboratory research spotlights double-stranded ribonucleic acid (dsRNA)-binding proteins. ...
PHILADELPPHIA—Patients were 28 percent more likely to get a flu shot when they got a text message reminder and their primary care provider already had an order for the shot waiting, new research from the Perelman School of Medicine showed. The study was published in JAMA Internal Medicine.
“This is important given the rise in vaccine hesitancy, which has resulted in a downward trend in flu vaccination that coincided with a high rate of hospitalization this flu season,” said the study’s lead author, Shivan Mehta, MD, MBA, MSHP, associate chief innovation officer at Penn Medicine. “Many nudge interventions directed to patients only on vaccinations have shown ...
LA JOLLA (January 27, 2026)—The COVID-19 pandemic gave us tremendous perspective on how wildly symptoms and outcomes can vary between patients experiencing the same infection. How can two people infected by the same pathogen have such different responses?
It largely comes down to variability in genetics (the genes you inherit) and life experience (your environmental, infection, and vaccination history). These two influences are imprinted on our cells through small molecular alterations called epigenetic changes, which shape cell identity ...
